Diligence memo · auto-generated · as of July 2, 2026
Inductive Bio, Inc.
Inductive Bio, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Inductive Bio, Inc. operates in Biotech / Pharma, based in BROOKLYN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inductive Bio, Inc. has raised $25M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2025-03-21.
Most recent recorded round closed around 2025-03-21.
Valuation (modeled)modeled
Provath models Inductive Bio, Inc. at approximately $132M (range $51M–$206M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.64× the median modeled value of Series B Biotech / Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 15 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 79% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Wheeler Bio, Inc., Abrexa Pharmaceuticals, Inc., Puna Bio Corp, Arpeggio Biosciences, Inc., Vinci Pharmaceuticals, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.